Stock 1877 SHANGHAI JUNSHI BIOSCIENCES CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Company Shanghai Junshi Biosciences Co., Ltd.

Equities

1877

CNE100003FF7

Pharmaceuticals

Market Closed - Hong Kong S.E.
Other stock markets
 04:09:09 2024-04-25 am EDT 		5-day change 1st Jan Change
10.24 HKD +5.24% Intraday chart for Shanghai Junshi Biosciences Co., Ltd. +6.11% -47.33%
08:20am Shanghai Junshi Biosciences Receives Hong Kong Approval for Cancer Drug Toripalimab MT
Apr. 24 Shanghai Junshi Biosciences Co., Ltd. Receives Notice from the Drug Office, Department of Health, the Government of the Hong Kong Special Administration Region CI

Business Summary

Shanghai Junshi Biosciences Co Ltd is a China-based company mainly engaged in innovation-driven biopharmaceutical business. The Company's main businesses are the discovery, clinical research and development of innovative drugs. The Company's main products include teriprizumab injection, Etesevimab, adalimumab injection and other drugs, which are used to treat malignant tumors, autoimmune system diseases, chronic metabolic diseases, nervous system diseases and infectious diseases . The Company is also engaged in the clinical research and development of recombinant humanized anti-PCSK9 monoclonal antibody injection and other drugs. The Company provides its products for domestic and overseas markets.

Number of employees: 2,568

Sales per Business

HKD in Million2022Weight2023Weight Delta
Innovative Drugs
100.0 %
1,690 100.0 % 1,660 100.0 % -1.77%

Sales per region

HKD in Million2022Weight2023Weight Delta
China
78.8 %
875 61.2 % 1,284 78.8 % +46.70%
Overseas
21.2 %
554 38.8 % 345 21.2 % -37.78%

Managers

Managers TitleAgeSince
Jianjun Zou CEO
 Chief Executive Officer 52 22-04-19
Zhuo Bing Zhang FOU
 Founder 57 12-12-26
Cong Li CEO
 Chief Executive Officer 60 16-12-21
Bao Hong Xu DFI
 Director of Finance/CFO 45 20-10-31
Jun Xiong CHM
 Chairman 50 15-03-26
Patricia Keegan CTO
 Chief Tech/Sci/R&D Officer - -
Gang Wang BRD
 Director/Board Member 67 19-08-28
Ning Li BRD
 Director/Board Member 63 18-01-07
Sheng Yao BRD
 Director/Board Member 49 14-05-31
Hui Feng BRD
 Director/Board Member 48 13-12-31

Members of the board

Members of the board TitleAgeSince
Cong Li CEO
 Chief Executive Officer 60 16-12-21
Yi Tang BRD
 Director/Board Member 56 15-05-29
Jun Xiong CHM
 Chairman 50 15-03-26
Hui Feng BRD
 Director/Board Member 48 13-12-31
Sheng Yao BRD
 Director/Board Member 49 14-05-31
Zhuo Bing Zhang FOU
 Founder 57 12-12-26
Zhi Qian BRD
 Director/Board Member 56 18-06-23
Yu Wu CHM
 Chairman 39 18-06-23
Ning Li BRD
 Director/Board Member 63 18-01-07
Chun Zhang BRD
 Director/Board Member 67 20-06-18

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 0 766,394,171 0 0 15.17 %
Stock B 1 219,295,700 149,560,900 ( 68.20 %) 0

Shareholders

NameEquities%Valuation
GREENLAND HOLDINGS CORPORATION LIMITED
23.43 %
51,386,400 23.43 % 65 M $
GIC Pte Ltd. (Investment Management)
6.997 %
15,344,289 6.997 % 19 M $
Loyal Valley Capital Co. Ltd.
5.891 %
12,918,902 5.891 % 16 M $
HHLR Advisors Ltd.
5.198 %
11,400,000 5.198 % 14 M $
UBS Asset Management (Hong Kong) Ltd.
1.426 %
3,128,000 1.426 % 4 M $
China Asset Management Co., Ltd.
0.7551 %
1,656,000 0.7551 % 2 M $
Bosera Asset Management Co., Ltd.
0.5847 %
1,282,200 0.5847 % 2 M $
Fullgoal Fund Management Co., Ltd.
0.3364 %
737,800 0.3364 % 930 447 $
Value Partners Ltd.
0.2317 %
508,000 0.2317 % 640 644 $
State Street Global Advisors Ltd.
0.1601 %
351,199 0.1601 % 442 901 $
NameEquities%Valuation
Jun Xiong
20.42 %
88,355,068 20.42 % 332 M $
Loyal Valley Capital Co. Ltd.
18.23 %
78,852,000 18.23 % 296 M $
Shenzhen Qianhai Yuanben Equity Investment Fund Management Co.
11.14 %
48,184,000 11.14 % 181 M $
Feng Xiang Xiong
9.491 %
41,060,000 9.491 % 154 M $
China Asset Management Co., Ltd.
6.497 %
28,105,380 6.497 % 106 M $
Yu Qing Zhou
5.012 %
21,680,800 5.012 % 81 M $
Hui Feng
3.047 %
13,180,000 3.047 % 50 M $
Zhen Hua Wang
2.545 %
11,010,194 2.545 % 41 M $
Wen Shi
2.545 %
11,010,194 2.545 % 41 M $
UBS Asset Management Switzerland AG
2.382 %
10,305,838 2.382 % 39 M $

Holdings

NameEquities%Valuation
SHANGHAI JUNSHI BIOSCIENCES CO., LTD.
0.46%
 2,000,000 0.46% 7,515,800 $

Company contact information

Shanghai Junshi Biosciences Co., Ltd.

13th Floor, Building 2 No. 36 & 58 Haiqu Road

201203, Shanghai

+

http://www.junshipharma.com
address Shanghai Junshi Biosciences Co., Ltd.(1877)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Biopharmaceuticals

Sales per region

Ratings for Shanghai Junshi Biosciences Co., Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
9.001 CNY
Average target price
22.5 CNY
Spread / Average Target
+149.97%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
SHANGHAI JUNSHI BIOSCIENCES CO., LTD. Stock Shanghai Junshi Biosciences Co., Ltd.
-47.33% 2.89B
CSL LIMITED Stock CSL Limited
-2.86% 87.31B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+3.95% 40.86B
BIOGEN INC. Stock Biogen Inc.
-21.94% 29.36B
UCB Stock UCB
+54.69% 24.49B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-5.41% 17.31B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-44.23% 11.26B
INCYTE CORPORATION Stock Incyte Corporation
-17.60% 11.62B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-13.96% 11.31B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+7.34% 8.31B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. 1877 Stock
  4. Company Shanghai Junshi Biosciences Co., Ltd.